Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells.

Ji Wook Moon, Soo Kyung Lee, Jung Ok Lee, Ji Hae Kim, Nami Kim, Jin Kim, Hyeon Soo Kim, Sun-Hwa Park

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Citations (Scopus)

Abstract

Methylation-mediated inactivation of tumor-suppressor genes is a critical event during the pathogenesis of many malignancies. Vincristine is a conventional anticancer drug used to treat various types of cancers. However, few studies describe the epigenetic-based effects of vincristine. In this study, changes in the methylation of runt-related transcription factor-3 (RUNX3) were investigated in CCD18Co normal colon cells and DLD-1 colorectal adenocarcinoma cells. CCD18Co and DLD-1 cells were treated with vincristine, and the methylation status was assessed using quantitative methylation-specific polymerase chain reaction (QMSP). Eleven normal colon tissues and 105 colorectal cancer tissues were investigated by methylation and mRNA expression of RUNX3 using QMSP and real-time reverse transcription polymerase chain reaction (real time-PCR). RUNX3 was demethylated after vincristine treatment in DLD-1 cells. The expression of RUNX3 mRNA was down-regulated in DLD-1 cells because of DNA hypermethylation, but was restored after vincristine treatment. In addition, hypermethylation of RUNX3 was detected in 70 out of 105 colorectal carcinomas (66.7%). RUNX3 hypermethylation was greater in colon cancer tissues than in rectal cancer tissues. The expression of RUNX3 mRNA was reduced in 68 out of 105 colorectal cancer tissues (64.8%). These results demonstrate that vincristine demethylates RUNX3 in colorectal adenocarcinoma cells, and restores its expression.

Original languageEnglish
Title of host publicationAnticancer research
Pages133-140
Number of pages8
Volume34
Edition1
Publication statusPublished - 2014

Fingerprint

Vincristine
Methylation
Adenocarcinoma
Colorectal Neoplasms
Messenger RNA
Colon
Transcription Factor 3
Polymerase Chain Reaction
Rectal Neoplasms
Tumor Suppressor Genes
Epigenomics
Colonic Neoplasms
Reverse Transcription
Real-Time Polymerase Chain Reaction
Neoplasms
DNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Moon, J. W., Lee, S. K., Lee, J. O., Kim, J. H., Kim, N., Kim, J., ... Park, S-H. (2014). Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells. In Anticancer research (1 ed., Vol. 34, pp. 133-140)

Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells. / Moon, Ji Wook; Lee, Soo Kyung; Lee, Jung Ok; Kim, Ji Hae; Kim, Nami; Kim, Jin; Kim, Hyeon Soo; Park, Sun-Hwa.

Anticancer research. Vol. 34 1. ed. 2014. p. 133-140.

Research output: Chapter in Book/Report/Conference proceedingChapter

Moon, JW, Lee, SK, Lee, JO, Kim, JH, Kim, N, Kim, J, Kim, HS & Park, S-H 2014, Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells. in Anticancer research. 1 edn, vol. 34, pp. 133-140.
Moon JW, Lee SK, Lee JO, Kim JH, Kim N, Kim J et al. Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells. In Anticancer research. 1 ed. Vol. 34. 2014. p. 133-140
Moon, Ji Wook ; Lee, Soo Kyung ; Lee, Jung Ok ; Kim, Ji Hae ; Kim, Nami ; Kim, Jin ; Kim, Hyeon Soo ; Park, Sun-Hwa. / Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells. Anticancer research. Vol. 34 1. ed. 2014. pp. 133-140
@inbook{ee0ea6dd1d144116bc1345976e8de3c1,
title = "Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells.",
abstract = "Methylation-mediated inactivation of tumor-suppressor genes is a critical event during the pathogenesis of many malignancies. Vincristine is a conventional anticancer drug used to treat various types of cancers. However, few studies describe the epigenetic-based effects of vincristine. In this study, changes in the methylation of runt-related transcription factor-3 (RUNX3) were investigated in CCD18Co normal colon cells and DLD-1 colorectal adenocarcinoma cells. CCD18Co and DLD-1 cells were treated with vincristine, and the methylation status was assessed using quantitative methylation-specific polymerase chain reaction (QMSP). Eleven normal colon tissues and 105 colorectal cancer tissues were investigated by methylation and mRNA expression of RUNX3 using QMSP and real-time reverse transcription polymerase chain reaction (real time-PCR). RUNX3 was demethylated after vincristine treatment in DLD-1 cells. The expression of RUNX3 mRNA was down-regulated in DLD-1 cells because of DNA hypermethylation, but was restored after vincristine treatment. In addition, hypermethylation of RUNX3 was detected in 70 out of 105 colorectal carcinomas (66.7{\%}). RUNX3 hypermethylation was greater in colon cancer tissues than in rectal cancer tissues. The expression of RUNX3 mRNA was reduced in 68 out of 105 colorectal cancer tissues (64.8{\%}). These results demonstrate that vincristine demethylates RUNX3 in colorectal adenocarcinoma cells, and restores its expression.",
author = "Moon, {Ji Wook} and Lee, {Soo Kyung} and Lee, {Jung Ok} and Kim, {Ji Hae} and Nami Kim and Jin Kim and Kim, {Hyeon Soo} and Sun-Hwa Park",
year = "2014",
language = "English",
volume = "34",
pages = "133--140",
booktitle = "Anticancer research",
edition = "1",

}

TY - CHAP

T1 - Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells.

AU - Moon, Ji Wook

AU - Lee, Soo Kyung

AU - Lee, Jung Ok

AU - Kim, Ji Hae

AU - Kim, Nami

AU - Kim, Jin

AU - Kim, Hyeon Soo

AU - Park, Sun-Hwa

PY - 2014

Y1 - 2014

N2 - Methylation-mediated inactivation of tumor-suppressor genes is a critical event during the pathogenesis of many malignancies. Vincristine is a conventional anticancer drug used to treat various types of cancers. However, few studies describe the epigenetic-based effects of vincristine. In this study, changes in the methylation of runt-related transcription factor-3 (RUNX3) were investigated in CCD18Co normal colon cells and DLD-1 colorectal adenocarcinoma cells. CCD18Co and DLD-1 cells were treated with vincristine, and the methylation status was assessed using quantitative methylation-specific polymerase chain reaction (QMSP). Eleven normal colon tissues and 105 colorectal cancer tissues were investigated by methylation and mRNA expression of RUNX3 using QMSP and real-time reverse transcription polymerase chain reaction (real time-PCR). RUNX3 was demethylated after vincristine treatment in DLD-1 cells. The expression of RUNX3 mRNA was down-regulated in DLD-1 cells because of DNA hypermethylation, but was restored after vincristine treatment. In addition, hypermethylation of RUNX3 was detected in 70 out of 105 colorectal carcinomas (66.7%). RUNX3 hypermethylation was greater in colon cancer tissues than in rectal cancer tissues. The expression of RUNX3 mRNA was reduced in 68 out of 105 colorectal cancer tissues (64.8%). These results demonstrate that vincristine demethylates RUNX3 in colorectal adenocarcinoma cells, and restores its expression.

AB - Methylation-mediated inactivation of tumor-suppressor genes is a critical event during the pathogenesis of many malignancies. Vincristine is a conventional anticancer drug used to treat various types of cancers. However, few studies describe the epigenetic-based effects of vincristine. In this study, changes in the methylation of runt-related transcription factor-3 (RUNX3) were investigated in CCD18Co normal colon cells and DLD-1 colorectal adenocarcinoma cells. CCD18Co and DLD-1 cells were treated with vincristine, and the methylation status was assessed using quantitative methylation-specific polymerase chain reaction (QMSP). Eleven normal colon tissues and 105 colorectal cancer tissues were investigated by methylation and mRNA expression of RUNX3 using QMSP and real-time reverse transcription polymerase chain reaction (real time-PCR). RUNX3 was demethylated after vincristine treatment in DLD-1 cells. The expression of RUNX3 mRNA was down-regulated in DLD-1 cells because of DNA hypermethylation, but was restored after vincristine treatment. In addition, hypermethylation of RUNX3 was detected in 70 out of 105 colorectal carcinomas (66.7%). RUNX3 hypermethylation was greater in colon cancer tissues than in rectal cancer tissues. The expression of RUNX3 mRNA was reduced in 68 out of 105 colorectal cancer tissues (64.8%). These results demonstrate that vincristine demethylates RUNX3 in colorectal adenocarcinoma cells, and restores its expression.

UR - http://www.scopus.com/inward/record.url?scp=84897027174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897027174&partnerID=8YFLogxK

M3 - Chapter

VL - 34

SP - 133

EP - 140

BT - Anticancer research

ER -